Search

Your search keyword '"Newell-Price, John"' showing total 640 results
Start Over Author "Newell-Price, John"
640 results on '"Newell-Price, John"'

201. Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing's disease (CD)

Author

Newell-Price, John, primary, Pivonello, Rosario, additional, Tabarin, Antoine, additional, Fleseriu, Maria, additional, Witek, Przemyslaw, additional, Gadelha, Monica, additional, Petersenn, Stephan, additional, Tauchmanova, Libuse, additional, Ravichandran, Shoba, additional, Roughton, Michael, additional, Lacroix, Andre, additional, and Biller, Beverly MK, additional

Published
2018
Full Text
View/download PDF

202. Long-term efficacy and safety of once-monthly pasireotide in patients with Cushing's disease: A Phase III extension study

Author

Fleseriu, Maria, primary, Petersenn, Stephan, additional, Biller, Beverly M K, additional, Kadioglu, Pinar, additional, De, Block Christophe, additional, T'Sjoen, Guy, additional, Vantyghem, Marie C, additional, Tauchmanova, Libuse, additional, Ravichandran, Shoba, additional, Roughton, Michael, additional, Lacroix, Andre, additional, and Newell-Price, John, additional

Published
2018
Full Text
View/download PDF

204. Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing's syndrome. Data from ERCUSYN

Author

Valassi, Elena, primary, Tabarin, Antoine, additional, Brue, Thierry, additional, Feelders, Richard A, additional, Reincke, Martin, additional, Neteia-Maier, Romana, additional, Toth, Miklos, additional, Yaneva, Maria, additional, Webb, Susan M, additional, Tsagarakis, Stylianos, additional, Chanson, Philippe, additional, Pfeifer, Marija, additional, Droste, Michael, additional, Komerdus, Irina, additional, Kastelan, Darko, additional, Maiter, Dominique, additional, Chabre, Olivier, additional, Franz, Holger, additional, Santos, Alicia, additional, Strasburger, Christian J, additional, Trainer, Peter J, additional, Newell-Price, John, additional, and Ragnarsson, Oskar, additional

Published
2018
Full Text
View/download PDF

205. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016

Author

McCormack, Ann, primary, Dekkers, Olaf M, additional, Petersenn, Stephan, additional, Popovic, Vera, additional, Trouillas, Jacqueline, additional, Raverot, Gerald, additional, Burman, Pia, additional, _, _, additional, Hubalewska-Dydejezky, Alicia, additional, Assie, Guillaume, additional, Bach, Leon, additional, Batisse-Lignier, Marie, additional, Berinder, Katarina, additional, Bilbao, Ismene, additional, Bonnet, Fabrice, additional, Bresson, Damien, additional, Bruno, Oscar, additional, Campdera, Mariana, additional, Caron, Philippe, additional, Castinetti, Frederic, additional, Ceccato, Filippo, additional, Chabre, Olivier, additional, Chanson, Philippe, additional, Christ, Emanuel, additional, Cloix, Lucie, additional, Cortet, Christine, additional, Criniere, Lise, additional, Cuatrecasas, Guillem, additional, Debono, Miguel, additional, Delemer, Brigitte, additional, Desailloud, Rachel, additional, Deutschbein, Timo, additional, Dusek, Tina, additional, Engström, Britt Eden, additional, Faustini-Fustini, Marco, additional, Franck, Schillo, additional, Garcia, Cyril, additional, Greenman, Yona, additional, Gil, Susana Mallea, additional, Mantovani, Giovanna, additional, Gurnell, Mark, additional, Heaney, Anthony, additional, Henley, David, additional, Higham, Claire, additional, Hoving, EW, additional, Höybye, Charlotte, additional, Ichihara, Atsuhiro, additional, Jaffrain-Rea, Marie-Lise, additional, Johannsson, Gudmundur, additional, Jorgensen, Jens Otto Lunde, additional, Jublanc, Christel, additional, Komor, Jan, additional, Korbonits, Marta, additional, Kralievic, Ivana, additional, Larrieu-Ciron, Delphine, additional, Lasolle, Helene, additional, Laws, Edward, additional, Losa, Marco, additional, Maiter, Dominique, additional, Marcocci, Claudio, additional, Marques, Olinda Castro, additional, Mazzuco, Tania Longo, additional, Micko, Alexander, additional, Bourcigaux, Nathalie, additional, Neggers, Sebastian, additional, Newell-Price, John, additional, Perez-Berida, Belén, additional, Ortiz, Leon D, additional, Ragnarsson, Oskar, additional, Ragonese, Marta, additional, Reincke, Martin, additional, Sadoul, Jean-Louis, additional, Shimatsu, Akira, additional, Syro, Luis V, additional, Taillandier, Luc, additional, Toth, Miklos, additional, Usui, Takeshi, additional, Valkusz, Zauzsanna, additional, Vila, Greisa, additional, Whitelaw, Ben, additional, and Zatelli, Maria Chiara, additional

Published
2018
Full Text
View/download PDF

206. Colaboradores

Author

Achermann, John C., Ahmann, Andrew J., Aiello, Lloyd P., Alexander, Erik K., Allen, Rebecca H., Anawalt, Bradley D., Anderson, Mark S., Arbeláez, Ana María, Atkinson, Mark A., Auchus, Richard J., Barker, Jennifer M., Basson, Rosemary, Berga, Sarah L., Bhadada, Sanjay K., Bhan, Arti, Bhasin, Shalender, Black, Dennis M., Boulton, Andrew J.M., Braunstein, Glenn D., Brennan, Annabelle, Brent, Gregory A., Bringhurst, F. Richard, Brito, Juan P., Brown, Todd T., Brownlee, Michael, Bulun, Serdar E., Bushinsky, David A., Carter-Su, Christin, Chan, Yee-Ming, Cohen, Ronald, Cooke, David W., Cooper, Mark E., Cousin, Ewerton, Cryer, Philip E., Dassau, Eyal, Dattani, Mehul T., de Paula, Francisco J.A., Demay, Marie B., DiVall, Sara A., Duncan, Bruce B., Feldman, Eva L., Ferrannini, Ele, Ferris, Heather A., Filetti, Sebastiano, Franco, Laercio J., Gevers, Evelien F., Ghigo, Ezio, Goldberg, Ira J., Goldfine, Allison B., Gottlieb, Peter A., Grinspoon, Steven K., Hannema, Sabine E., Hayes, Frances J., Hickey, Martha, Hirschorn, Joel. N., Ho, Ken, Hollenberg, Anthony, Hughes, Ieuan A., Kahn, C. Ronald, Kaiser, Ursula, Katugampola, Harshini, Kaunitz, Andrew M., Koenig, Ronald J., Kopp, Peter A., Kronenberg, Henry M., Laffel, Lori, Lamberts, Steven W.J., Lanfranco, Fabio, Larsen, P. Reed, Leboulleux, Sophie, Lechan, Ronald M., Majithia, Amit R., Maraka, Spyridoula, Maratos-Flier, Eleftheria, Mari, Andrea, Matsumoto, Alvin M., McGill, Dayna E., Melmed, Shlomo, Montori, Victor, Myers, Martin G., Jr., Newell-Price, John D.C., Newey, Paul J., Nitsche, Joshua F., Öberg, Kjell, Olson, David P., O’Neill, Brian T., Ospina, Naykky Singh, Plutzky, Jorge, Polonsky, Kenneth S., Radovick, Sally, Rao, Ajay D., Rao, Sudhaker D., Riddle, Matthew C., Rodriguez-Gutierrez, Rene, Rosen, Clifford J., Rosen, Evan D., Rosenthal, Stephen M., Salama, Mahmoud, Salvatore, Domenico, Sandler, Victoria, Schmidt, Maria Inês, Semenkovich, Clay F., Sluss, Patrick M., Strasburger, Christian J., Styne, Dennis M., Sun, Jennifer K., Tangpricha, Vin, Thakker, Rajesh V., Thomas, Robert L., Thompson, Christopher J., Tuttle, R. Michael, van den Beld, Annewieke W., Verbalis, Joseph G., Weetman, Anthony P., Wiersinga, Wilmar M., Woodruff, Teresa K., and Young, William F., Jr.

Published
2021
Full Text
View/download PDF

208. Contributors to Davidson’s Principles and Practice of Medicine, 23rd Edition

Author

Angus, Brian J, Anstee, Quentin M, Burnett, Leslie, Byers, Mark, Campbell, Harry, Clunie, Gavin PR, Colvin, Lesley A, Conway, Bryan, Cooper, Nicola, Cracknell, Alison L, Culligan, Dominic J, Dark, Graham G, Davenport, Richard J, Dockrell, David H, El-Omar, Emad, Fallon, Marie, FitzPatrick, David R, Grubb, Neil R, Ibbotson, Sally H, Innes, J Alastair, Jenks, Sara J, Johnston, Sarah L, Jones, David EJ, Langhorne, Peter, Lawrie, Stephen M, Leach, John Paul, Maartens, Gary, Mackillop, Lucy, MacMahon, Michael J, Mann BMedSci, Rebecca, Manson, Lynn M, Marshall, Sara E, Mather, Amanda, Maxwell, Simon R, McAllister, David A, McCrimmon, Rory J, McLean, Mairi, Neuberger, Francesca EM, Newby, David E, Newell-Price, John DC, Olson, John, Pearson, Ewan R, Phelan, Paul J, Ralston, Stuart H, Reid, Peter T, Sandoe, Jonathan AT, Scott, Gordon R, Shand, Alan G, Steel, Robby M, Stewart, Grant D, Stewart, Peter, Strachan, Mark WJ, Sullivan, David R, Sundar, Shyam, Tallentire, Victoria R, Tatton-Brown, Katrina, Thomas, Simon HL, Watson, Henry G, White, Julian, Wilding, John PH, and Witham, Miles D

Published
2021
Full Text
View/download PDF

210. Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN.

Author

UCL - (SLuc) Service d'endocrinologie et de nutrition, Valassi, Elena, Feelders, Richard, Maiter, Dominique, Chanson, Philippe, Yaneva, Maria, Reincke, Martin, Krsek, Michal, Tóth, Miklós, Webb, Susan M, Santos, Alicia, Paiva, Isabel, Komerdus, Irina, Droste, Michael, Tabarin, Antoine, Strasburger, Christian J, Franz, Holger, Trainer, Peter J, Newell-Price, John, Wass, John Ah, Papakokkinou, Eleni, Ragnarsson, Oskar, ERCUSYN Study Group, UCL - (SLuc) Service d'endocrinologie et de nutrition, Valassi, Elena, Feelders, Richard, Maiter, Dominique, Chanson, Philippe, Yaneva, Maria, Reincke, Martin, Krsek, Michal, Tóth, Miklós, Webb, Susan M, Santos, Alicia, Paiva, Isabel, Komerdus, Irina, Droste, Michael, Tabarin, Antoine, Strasburger, Christian J, Franz, Holger, Trainer, Peter J, Newell-Price, John, Wass, John Ah, Papakokkinou, Eleni, Ragnarsson, Oskar, and ERCUSYN Study Group

Abstract

Hypercortisolism in Cushing's syndrome (CS) is associated with impaired health-related quality of life (HRQoL), which may persist despite remission. We used the data entered into the European Registry on Cushing's syndrome (ERCUSYN) to evaluate if patients with CS of pituitary origin (PIT-CS) have worse HRQoL, both before and after treatment than patients with adrenal causes (ADR-CS). Data from 595 patients (492 women; 83%) who completed the CushingQoL and/or EQ-5D questionnaires at baseline and/or following treatment were analysed. At baseline, HRQoL did not differ between PIT-CS (n = 293) and ADR-CS (n = 120) on both EuroQoL and CushingQoL. Total CushingQoL score in PIT-CS and ADR-CS was 41 ± 18 and 44 ± 20, respectively (P = .7). At long-time follow-up (>1 year after treatment) total CushingQoL score was however lower in PIT-CS than ADR-CS (56 ± 20 vs 62 ± 23; P = .045). In a regression analysis, after adjustment for baseline age, gender, remission status, duration of active CS, glucocorticoid dependency and follow-up time, no association was observed between aetiology and HRQoL. Remission was associated with better total CushingQoL score (P < .001), and older age at diagnosis with worse total score (P = .01). Depression at diagnosis was associated with worse total CushingQoL score at the last follow-up (P < .001). PIT-CS patients had poorer HRQoL than ADR-CS at long-term follow-up, despite similar baseline scoring. After adjusting for remission status, no interaetiology differences in HRQoL scoring were found. Age and presence of depression at diagnosis of CS may be potential predictors of worse HRQoL regardless of CS aetiology.

Published
2018

213. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

Author

Lacroix, André, primary, Gu, Feng, additional, Gallardo, Wilson, additional, Pivonello, Rosario, additional, Yu, Yerong, additional, Witek, Przemysław, additional, Boscaro, Marco, additional, Salvatori, Roberto, additional, Yamada, Masanobu, additional, Tauchmanova, Libuse, additional, Roughton, Michael, additional, Ravichandran, Shoba, additional, Petersenn, Stephan, additional, Biller, Beverly M K, additional, Newell-Price, John, additional, Arnaldi, Giorgio, additional, Asha, Hesarghatta Shyamasunder, additional, Bandgar, Tushar, additional, Barkan, Ariel, additional, Biering, Henrik, additional, Bex, Marie, additional, Bolanowski, Marek, additional, Bronstein, Marcello Delano, additional, Brue, Thierry, additional, Bruera, Dario, additional, Cavagnini, Francesco, additional, Comlekci, Abdurrahman, additional, De Block, Christophe, additional, Delibasi, Tuncay, additional, Fajardo-Montañana, Carmen, additional, Feelders, Richard Abraham, additional, Fleseriu, Maria, additional, Gadelha, Monica Roberto, additional, Geer, Eliza Brevoort, additional, Heaney, Anthony, additional, Houde, Ghislaine, additional, Ichihara, Atsuhiro, additional, Imran, Syed Ali, additional, Ioachimescu, Adriana, additional, Kadioglu, Pinar, additional, Li, Yiming, additional, Loli, Paola, additional, Nishiyama, Mitsuru, additional, Rozhinskaya, Liudmila, additional, Ruchala, Marek, additional, Saitoh, Youichi, additional, Schöfl, Christof, additional, Schopohl, Jochen, additional, Shimatsu, Akira, additional, Shimizu, Chikara, additional, Snabboon, Thiti, additional, Snyder, Peter, additional, Suzaki, Noriyuki, additional, Tabarin, Antoine, additional, Takahashi, Yutaka, additional, Britto, Susana Tara, additional, T'Sjoen, Guy, additional, Vantyghem, Marie-Christine, additional, Velkeniers, Brigitte, additional, Webb, Susan, additional, and Yamada, Shozo, additional

Published
2018
Full Text
View/download PDF

214. Contributors

Author

Achermann, John C., Ahmann, Andrew J., Aiello, Lloyd P., Alexander, Erik K., Allen, Rebecca H., Anawalt, Bradley D., Anderson, Mark S., Arbeláez, Ana María, Atkinson, Mark A., Auchus, Richard J., Barker, Jennifer M., Basson, Rosemary, Berga, Sarah L., Bhadada, Sanjay K., Bhan, Arti, Bhasin, Shalender, Black, Dennis M., Boulton, Andrew J.M., Braunstein, Glenn D., Brennan, Annabelle, Brent, Gregory A., Bringhurst, F. Richard, Brito, Juan P., Brown, Todd T., Brownlee, Michael, Bulun, Serdar E., Bushinsky, David A., Carter-Su, Christin, Chan, Yee-Ming, Cohen, Ronald, Cooke, David W., Cooper, Mark E., Cousin, Ewerton, Cryer, Philip E., Dassau, Eyal, Dattani, Mehul T., de Paula, Francisco J.A., Demay, Marie B., DiVall, Sara A., Duncan, Bruce B., Feldman, Eva L., Ferrannini, Ele, Ferris, Heather A., Filetti, Sebastiano, Franco, Laercio J., Gevers, Evelien F., Ghigo, Ezio, Goldberg, Ira J., Goldfine, Allison B., Gottlieb, Peter A., Grinspoon, Steven K., Hannema, Sabine E., Hayes, Frances J., Hickey, Martha, Hirschorn, Joel. N., Ho, Ken, Hollenberg, Anthony, Hughes, Ieuan A., Kahn, C. Ronald, Kaiser, Ursula, Katugampola, Harshini, Kaunitz, Andrew M., Koenig, Ronald J., Kopp, Peter A., Kronenberg, Henry M., Laffel, Lori, Lamberts, Steven W.J., Lanfranco, Fabio, Larsen, P. Reed, Leboulleux, Sophie, Lechan, Ronald M., Majithia, Amit R., Maraka, Spyridoula, Maratos-Flier, Eleftheria, Mari, Andrea, Matsumoto, Alvin M., McGill, Dayna E., Melmed, Shlomo, Montori, Victor, Myers, Martin G., Jr., Newell-Price, John D.C., Newey, Paul J., Nitsche, Joshua F., Öberg, Kjell, Olson, David P., O’Neill, Brian T., Ospina, Naykky Singh, Plutzky, Jorge, Polonsky, Kenneth S., Radovick, Sally, Rao, Ajay D., Rao, Sudhaker D., Riddle, Matthew C., Rodriguez-Gutierrez, Rene, Rosen, Clifford J., Rosen, Evan D., Rosenthal, Stephen M., Salama, Mahmoud, Salvatore, Domenico, Sandler, Victoria, Schmidt, Maria Inês, Semenkovich, Clay F., Sluss, Patrick M., Strasburger, Christian J., Styne, Dennis M., Sun, Jennifer K., Tangpricha, Vin, Thakker, Rajesh V., Thomas, Robert L., Thompson, Christopher J., Tuttle, R. Michael, van den Beld, Annewieke W., Verbalis, Joseph G., Weetman, Anthony P., Wiersinga, Wilmar M., Woodruff, Teresa K., and Young, William F., Jr.

Published
2020
Full Text
View/download PDF

235. Outcomes of Patients with Nelson’s Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers

Author

Fountas, Athanasios, Lim, Eugenie S, Drake, William M, Powlson, Andrew S, Gurnell, Mark, Martin, Niamh M, Seejore, Khyatisha, Murray, Robert D, MacFarlane, James, Ahluwalia, Rupa, Swords, Francesca, Ashraf, Muhammad, Pal, Aparna, Chong, Zhuomin, Freel, Marie, Balafshan, Tala, Purewal, Tejpal S, Speak, Rowena G, Newell-Price, John, Higham, Claire E, Hussein, Ziad, Baldeweg, Stephanie E, Dales, Jolyon, Reddy, Narendra, Levy, Miles J, and Karavitaki, Niki

Published
2020
Full Text
View/download PDF

236. Subacute thyroiditis following COVID‐19 vaccination: Case report and Society for Endocrinology survey.

Author

Bennet, William M., Elamin, Aisha, and Newell‐Price, John D.

Subjects
THYROIDITIS, COVID-19 vaccines, COVID-19 pandemic, ENDOCRINOLOGY, MOLECULAR mimicry, CELL receptors
Abstract

We report a case of subacute thyroiditis which developed following COVID-19 vaccination and 17 additional cases also presenting after COVID-19 vaccination. Subacute thyroiditis following COVID-19 vaccination: Case report and Society for Endocrinology survey It has also been reported that Graves' disease can develop shortly following COVID-19 vaccination.[5] With billions of COVID-19 vaccine doses administered to date, and a background subacute thyroiditis incidence of 4.9 per 100,000, there remains a caveat that the cases in our survey may have arisen by chance. [Extracted from the article]

Published
2023
Full Text
View/download PDF

243. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors

Author

Fassnacht, Martin, primary, Arlt, Wiebke, additional, Bancos, Irina, additional, Dralle, Henning, additional, Newell-Price, John, additional, Sahdev, Anju, additional, Tabarin, Antoine, additional, Terzolo, Massimo, additional, Tsagarakis, Stylianos, additional, and Dekkers, Olaf M, additional

Published
2016
Full Text
View/download PDF

247. Radiosurgery as primary management for acromegaly.

Author

Sims‐Williams, Hugh P., Rajapaksa, Kaveesha, Sinha, Saurabh, Radatz, Matthias, Walton, Lee, Yianni, John, and Newell‐Price, John

Subjects
BONE diseases, ACROMEGALY, RADIOSURGERY, HYPERTROPHY, NEUROSURGERY, PITUITARY diseases
Abstract

Objective: Transsphenoidal surgery (TSS) remains the recommended primary treatment for acromegaly. Long‐term outcome data are not available for patients treated with gamma knife radiosurgery (STRS) as a primary treatment. Design: Retrospective cohort study. Data collection: notes review, laboratory results, general physician notes, patient questionnaire and death certification. Patients: Twenty acromegaly patients underwent primary STRS at the National Centre for Radiosurgery, Sheffield, UK, between 1985 and 2015. Measurements: Biochemical control (GH/IGF1), hypopituitarism, morbidity and mortality were all recorded. Results: At 20 years of follow‐up, control was seen in all on acromegaly‐specific medication (n = 12) and 75% of those off medication (3/4). Time for 50% to achieve control on medication was 3 years, and 7.4 years off medication. Median marginal radiation dose was 27.5 Gy, and median follow‐up was 166.5 months. 53% of patients developed new hypopituitarism at a median follow‐up of 146 months, and the development of first onset of hypopituitarism occurred as late as 20 years after treatment. With MRI planning, no other complications were noted. Three patients underwent subsequent TSS due to poor biochemical control. During follow‐up, 7 patients died at a median age of 65 years. There were no STRS‐related deaths. Conclusion: This is the longest follow‐up of patients who have undergone primary STRS for acromegaly. It shows low morbidity, but significant latency to biochemical control and new‐onset hypopituitarism. This mandates very long‐term follow‐up for these patients. STRS has shown good long‐term efficacy providing initial control can be afforded by optimal medical management. While TSS remains best practice, STRS offers an alternative for those in whom surgery is not an option. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

248. Development of a rapid liquid chromatography tandem mass spectrometry method for the quantitation of serum dexamethasone and its clinical verification.

Author

Hawley, James M., Owen, Laura J., Debono, Miguel, Newell-Price, John, and Keevil, Brian G.

Subjects
LIQUID chromatography-mass spectrometry, CUSHING'S syndrome, ADRENAL cortex diseases, ENDOCRINE diseases, GLUCOCORTICOIDS, CLINICAL pathology, DRUG stability, LIQUID chromatography, MASS spectrometry, RESEARCH evaluation, TIME, DEXAMETHASONE
Abstract

Background Measurement of serum dexamethasone during the overnight dexamethasone-suppression test has been recommended to reduce false-positive results when investigating Cushing's syndrome or increasingly commonly found adrenal incidentalomas. Despite this, there remains a paucity of well-validated dexamethasone methods currently available. Here, we describe the development of a rapid and sensitive liquid chromatography tandem mass spectrometry serum dexamethasone assay and verify its utility in a cohort of postmenopausal females. Method Isotopically labelled internal standard was added to samples prior to supported liquid extraction. Extracts were analysed using liquid chromatography tandem mass spectrometry in the positive electrospray ionization mode. Multiple reaction monitoring was used to detect dexamethasone and its corresponding internal standard transitions. Normal healthy postmenopausal women ( n = 95) were recruited and underwent an overnight dexamethasone suppression test, with serum dexamethasone and cortisol measurements at 09:00 after administration of oral dexamethasone 1 mg at 23:00 the night before. Results Mean intra- and inter-assay imprecision were 4.1% and 2.9%, respectively, for dexamethasone concentrations of 1.5, 6.0 and 12.0 nmol/L. Matrix effects were found to be negligible at 106-109% with recovery ranging from 96 to 100%. The limit of quantitation was 0.25 nmol/L, and structural analogue analysis proved the method to be robust against interferences. Applying a serum dexamethasone cut-off of >3.3 nmol/L was associated with a serum cortisol ≤50 nmol/L in 84/95 individuals. Conclusion We have developed a sensitive and robust liquid chromatography tandem mass spectrometry method for the quantitation of serum dexamethasone. The method can be used to identify false-positive results during the overnight dexamethasone suppression test or for pharmacokinetic studies. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

249. Advances in the medical treatment of Cushing's syndrome

Author

Feelders, Richard A, Newell-Price, John, Pivonello, Rosario, Nieman, Lynnette K, Hofland, Leo J, and Lacroix, Andre

Abstract

Cushing's syndrome is associated with multisystem morbidity and, when suboptimally treated, increased mortality. Medical therapy is an option for patients if surgery is not successful and can be classified into pituitary-directed drugs, steroid synthesis inhibitors, and glucocorticoid receptor antagonists. In the last decade there have been new developments in each drug category. Targeting dopamine and somatostatin receptors on corticotroph adenomas with cabergoline or pasireotide, or both, controls cortisol production in up to 40% of patients. Potential new targets in corticotroph adenomas include the epidermal growth factor receptor, cyclin-dependent kinases, and heat shock protein 90. Osilodrostat and levoketoconazole are new inhibitors of steroidogenesis and are currently being evaluated in multicentre trials. CORT125134 is a new selective glucocorticoid receptor antagonist under investigation. We summarise the drug therapies for various forms of Cushing's syndrome and focus on emerging drugs and drug targets that have the potential for new and effective tailor-made pharmacotherapy for patients with Cushing's syndrome.

Published
2019
Full Text
View/download PDF

250. Salivary Cortisone to Estimate Cortisol Exposure and Sampling Frequency Required Based on Serum Cortisol Measurements.

Author

Harrison, Robert F, Debono, Miguel, Whitaker, Martin J, Keevil, Brian G, Newell-Price, John, and Ross, Richard J

Abstract

Population studies frequently measure cortisol as a marker of stress, and excess cortisol is associated with increased mortality. Cortisol has a circadian rhythm, and frequent blood sampling is impractical to assess cortisol exposure. We investigated measuring salivary cortisone and examined the sampling frequency required to determine cortisol exposure.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results